Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 12;9(2):431. doi: 10.3390/cells9020431

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The phenotype and differences in the expression of CD146 and CD271 antigens on MSCs of patients with NMHD. (A) Phenotype of passage 2 MSCs in a patient with TM. MSCs were immunostained with fluorochrome-conjugated monoclonal antibodies and incubated at 4 °C for 30 min. After two wash steps with PBS + 0.2% BSA the stained cells were analyzed on a FACSCalibur (Becton-Dickinson, Heidelberg) equipped with Macintosh software for data analysis (CellQuest). At least 50.000 events were acquired for each measurement. (B) Expression of CD146 antigen on MSCs of passage 2 in patients with TM (68.2% (43.8–89.3), N = 10) and SCD (68.7% (46.7–75.4) N = 9)) was significantly lower than in MSCs of healthy controls (97.65% (80.6–99.8), N = 12, P < 0.0001). (C) Passage 2 MSCs of patients with non-malignant hematological diseases expressed similar levels of CD271 antigen as MSCs of healthy donors. Co: Control, TM: thalassemia major, SCD: sickle cell disease, SCN: severe congenital neutropenia.

The phenotype and differences in the expression of CD146 and CD271 antigens on MSCs of patients with NMHD. (A) Phenotype of passage 2 MSCs in a patient with TM. MSCs were immunostained with fluorochrome-conjugated monoclonal antibodies and incubated at 4 °C for 30 min. After two wash steps with PBS + 0.2% BSA the stained cells were analyzed on a FACSCalibur (Becton-Dickinson, Heidelberg) equipped with Macintosh software for data analysis (CellQuest). At least 50.000 events were acquired for each measurement. (B) Expression of CD146 antigen on MSCs of passage 2 in patients with TM (68.2% (43.8–89.3), N = 10) and SCD (68.7% (46.7–75.4) N = 9)) was significantly lower than in MSCs of healthy controls (97.65% (80.6–99.8), N = 12, P < 0.0001). (C) Passage 2 MSCs of patients with non-malignant hematological diseases expressed similar levels of CD271 antigen as MSCs of healthy donors. Co: Control, TM: thalassemia major, SCD: sickle cell disease, SCN: severe congenital neutropenia.